Fluidigm, NanoString Reach Settlement on Lawsuit Alleging False Advertising, Other Charges | GenomeWeb

NEW YORK (GenomeWeb News) – Fluidigm and NanoString Technologies have settled lawsuits filed by Fluidigm that accused NanoString of false advertising, unfair competition, and unlawful trade practice, the companies announced after the close of the market on Tuesday.

As part of the settlement, NanoString is required to remove all references to a single-cell comparison study of Fluidigm's and NanoString's single-cell products, and to recall and destroy all materials related to and/or based on the study, Fluidigm said.

Financial terms of the settlement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.